Department of Gastroenterology and Hepatology, Amsterdam UMC - Locatie AMC, Amsterdam, The Netherlands
Department of Gastroenterology and Hepatology, Amsterdam UMC - Locatie AMC, Amsterdam, The Netherlands.
J Clin Pathol. 2021 Jan;74(1):48-52. doi: 10.1136/jclinpath-2020-206511. Epub 2020 May 28.
The histopathological diagnosis of low-grade dysplasia (LGD) in Barrett's oesophagus (BO) is associated with poor interobserver agreement and guidelines dictate expert review. To facilitate nationwide expert review in the Netherlands, a web-based digital review panel has been set up, which currently consists of eight 'core' pathologists. The aim of this study was to evaluate if other pathologists from the Dutch BO expert centres qualify for the expert panel by assessing their performance in 80 consecutive LGD reviews submitted to the panel.
Pathologists independently assessed digital slides in two phases. Both phases consisted of 40 cases, with a group discussion after phase I. For all cases, a previous consensus diagnosis made by five core pathologists was available, which was used as reference. The following criteria were used: (1) percentage of 'indefinite for dysplasia' diagnoses, (2) percentage agreement with consensus diagnosis and (3) proportion of cases with a consensus diagnosis of dysplasia underdiagnosed as non-dysplastic. Benchmarks were based on scores of the core pathologists.
After phase I, 1/7 pathologists met the benchmark score for all quality criteria, yet three pathologists only marginally failed the agreement with consensus diagnosis (score 68.3%, benchmark 69%). After a group discussion and phase II, 5/6 remaining aspirant panel members qualified with all scores within the benchmark range.
The Dutch BO review panel now consists of 14 pathologists, who-after structured assessments and group discussions-can be considered homogeneous in their review of biopsies with LGD.
巴雷特食管(BO)中低级别异型增生(LGD)的组织病理学诊断一致性较差,指南建议进行专家审查。为了便于在荷兰进行全国性的专家审查,已经建立了一个基于网络的数字审查小组,目前由 8 名“核心”病理学家组成。本研究的目的是通过评估 80 例连续提交给小组的 LGD 病例的表现,评估荷兰 BO 专家中心的其他病理学家是否有资格成为专家小组成员。
病理学家在两个阶段独立评估数字切片。两个阶段均包含 40 例病例,第一阶段后进行小组讨论。对于所有病例,均提供了 5 名核心病理学家的先前共识诊断作为参考。使用以下标准:(1)“不确定为异型增生”诊断的百分比,(2)与共识诊断的百分比一致性,以及(3)共识诊断为异型增生的病例中被误诊为非异型增生的比例。基准是基于核心病理学家的分数。
第一阶段后,有 1/7 名病理学家满足所有质量标准的基准分数,但有 3 名病理学家仅在与共识诊断的一致性方面略有不足(分数 68.3%,基准 69%)。经过小组讨论和第二阶段,6 名剩余的候选小组成员中的 5 名获得了资格,所有分数均在基准范围内。
荷兰 BO 审查小组现在由 14 名病理学家组成,他们在对具有 LGD 的活检进行审查时,可以通过结构化评估和小组讨论被认为是同质的。